🚨 Important EGFR-mutated NSCLC results at #ESMO26!
Phase III SAFFRON (N=338):
Osimertinib + savolitinib vs platinum–pemetrexed after osimertinib progression, with high MET overexpression and/or amplification.
OS: 17.8 vs 12.9 mo
HR 0.68 (95% CI 0.50–0.91)
30 views · 2 likes · 2 reposts · 3 replies
- gilberto lopes@GlopesMd
@SclcSMASHERS @FDA @LUNGevity @lungoncdoc @StephenVLiu @HHorinouchi @g_mountzios @sands_jacob @LauraAlderMD @oncodaily @OncoAlert @Latinamd @LuisPaz_Ares @RManochakian @LuisRaezMD @triparnasen @LaurenByersMD @LungCancerEu @alissajcooper @BZhangMD @NaglaAKarimMD @Annechiangmd @IASLC @NCCN @ASCO #ESMO26 @larvol @tribeMDUS @sylvestercancer @oncbrothers @chinmay @Jani_Chinmay @colazagasti @openmedicineHQ @myesmo @openmedkate @openmedben @chadinabhan @YoungLungCancer @OncodailyLung @ClinicalLung #LCSM @LungPolicy @dan_morgxen @LAGurwitch
- gilberto lopes@GlopesMd
Key message: Test for MET-mediated resistance. Adding MET inhibition while maintaining EGFR suppression improves survival in biomarker-selected disease. Next: sequencing, CNS outcomes, and access. Lu et al. ESMO LBA6 / NEJM 2026.
- gilberto lopes@GlopesMd
PFS: 7.6 vs 5.4 mo HR 0.55 (0.42–0.72) #LCSM Additional SAFFRON results: ORR: 51% vs 27% 12-mo OS: 70% vs 53% MET-amplified subgroup: PFS: 7.6 vs 4.2 mo HR 0.487 (0.35–0.66) Subgroup not formally tested. Grade ≥3 TEAEs: 64% vs 63%.
Source: gilberto lopes · x.com